Mimetics of CD4 that inhibit immune response

Details Mimetics of CD4 that inhibit immune response Mimetics of CD4 that inhibit immune response

2008-03-18

2008-03-18

Canella, Karen A. (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C514S183000, C530S323000, C530S332000, C930S270000

Reexamination Certificate

active

07345020

ABSTRACT:
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C—C′ loop of the D1 domain; residues 317-323, the C—C′ loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

REFERENCES:
patent: 4963657 (1990-10-01), Pixley
patent: 5109123 (1992-04-01), Reinherz et al.
patent: WO 92/20704 (1992-11-01), None
patent: WO 93/24518 (1993-12-01), None
patent: WO 94/11014 (1994-05-01), None
Chen et al (PNAS, 1992, vol. 89, pp. 5872-5876).
Sierra and de la Torre, Angew. Chem Int Ed., 2000, vol. 39, pp. 1538-1559.
Nakanishi, et al., 1993,Gene, 137, 51-56.
Acha-Orbea et al.,Cell54:263-273 (1988).
Hafler et al.,J. Immunol. 141:131-138 (1988).
Jameson et al.,Nature368:744-746 (1994).
Lindsey et al.,Annals of Neurology36:183-189 (1994).
Racadot et al.,J. Autoimmunity6:771-786 (1993).
Steinman et al.,Proc. Natl. Acad. Sci. USA78:7111-7114 (1981).
Waldor et al.,Science227:415-17 (1985).
Wraith et al.,Cell59:247-255 (1989).
Zhang et al.,Nature Biotechnology14:472-475 (1996).
Satoh et al.,BBRC224:438-443 (1996).
Osband et al.Immunology Today11(6):193-195 (1990).
Mehta et al., “Synthetic Peptides of Human CD4 Enhance Binding of Immunoglobulins to Moncyte/Macrophage Cells,”Cellular Immunology156:146-154 (1994).
Goodman et al., “Topochemical Design of Bioactive Peptides and Peptidomimetics”, 18(10-11):1375-1393 (1992).
Mikayama et al.,PNAS90:10056-10060 (1993).
Lazar et al.,Mol. Cell Biol., 8:1247-1252 (1988).
Bowie et al.,Science247:1306-1310 (1990).
Ngo et al., inThe Protein Folding Problem and Tertiary Structure Prediction(ed.), Birkhauser, Boston MA pp. 433, 492-495 (1994).
Jelokhani-Niaraki et al.,Biochem J., 349:747-755 (2000).

Affiliated with

Also associated with

Rating

Mimetics of CD4 that inhibit immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mimetics of CD4 that inhibit immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mimetics of CD4 that inhibit immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2794213